scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Rhea-AI Summary

scPharmaceuticals (Nasdaq: SCPH) will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ World Headquarters in New York on May 20, 2024, at 11:00AM ET.

John Tucker, President & CEO, will present and meet with investors. The company's focus is on developing and commercializing products to optimize the delivery of infused therapies, improve patient care, and reduce healthcare costs. The presentation will be webcast and available in the Investor Relations section of the company's website.

Positive

• Participation in a prominent investor conference can increase visibility for SCPH.
• Opportunity to present and directly engage with potential investors.
• Webcast availability can reach a broader audience beyond conference attendees.

Negative

• No new financial or clinical data disclosed in the PR, limiting immediate impact on investor decision-making.
• Potential for stock price volatility around the event date based on presentation performance.

BURLINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the H.C. Wainwright 2^nd Annual BioConnect Investor Conference, which will be held at the NASDAQ World Headquarters in New York on Monday, May 20, at 11:00AM ET. Mr. Tucker will also be meeting with investors during the event.

A webcast of the presentation can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scPharmaceuticals.com.

About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead program focuses on the subcutaneous, self-administration of IV-strength treatment in heart failure. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
kmiranda@scpharma.com

Investors:
PJ Kelleher
LifeSci Advisors, 617-430-7579
pkelleher@lifesciadvisors.com 

FAQ

When will SCPH present at the H.C. Wainwright BioConnect Investor Conference?

scPharmaceuticals will present on May 20, 2024, at 11:00AM ET.

Where is the H.C. Wainwright BioConnect Investor Conference held?

The conference will be held at the NASDAQ World Headquarters in New York.

Who will present for SCPH at the H.C. Wainwright BioConnect Investor Conference?

John Tucker, President & CEO of scPharmaceuticals, will present.

How can I access the SCPH presentation at the H.C. Wainwright BioConnect Investor Conference?

A webcast of the presentation will be available in the Investor Relations section of scPharmaceuticals' website.

What is SCPH's primary business focus?

scPharmaceuticals focuses on developing and commercializing products that optimize the delivery of infused therapies, improve patient care, and reduce healthcare costs.